jlink
Tuesday, December 10, 2019

israel21C—Australia-based PhytoTech Medical has signed an exclusive licensing and collaboration agreement with Yissum, the technology-transfer company of the Hebrew University of Jerusalem, to develop, manufacture and market a novel delivery system to enhance the bioavailability of cannabidiol (CBD) and/or THC, the active ingredients in cannabis, for the treatment of a variety of medical indications. The novel formulations are based on technologies developed by Professors Abraham Domb and Amnon Hoffman from the Institute of Drug Research at the university’s School of Pharmacy.

Cannabis-based medications are currently in clinical use worldwide. The most known formulation is a sublingual spray delivering CBD and THC. PhytoTech plans to develop an improved oral capsule and transbuccal (through the cheek) delivery system consisting of a flexible adhesive patch that will release the active ingredients of cannabis in a controlled manner.